Literature DB >> 8989223

Treatment of scan-negative, thyroglobulin-positive metastatic thyroid cancer using radioiodine 131I and recombinant human thyroid stimulating hormone.

A Z Rudavsky1, L M Freeman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 8989223     DOI： 10.1210/jcem.82.1.3696

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  15 in total

Review 1.  The use of recombinant human thyrotropin (rhTSH) in the management of differentiated thyroid cancer.

Authors:  M C Skarulis
Journal:  Rev Endocr Metab Disord       Date:  2000-04       Impact factor: 6.514

2.  Role of Recombinant Human Thyrotropin (rhTSH) in the Treatment of Well-Differentiated Thyroid Cancer.

Authors:  E Robenshtok; R Michael Tuttle
Journal:  Indian J Surg Oncol       Date:  2011-12-20

3.  Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin.

Authors:  Joanna Klubo-Gwiezdzinska; Kenneth D Burman; Douglas Van Nostrand; Mihriye Mete; Jacqueline Jonklaas; Leonard Wartofsky
Journal:  Thyroid       Date:  2012-02-07       Impact factor: 6.568

Review 4.  Papillary thyroid cancer: medical management and follow-up.

Authors:  Richard T Kloos
Journal:  Curr Treat Options Oncol       Date:  2005-07

5.  Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone.

Authors:  G Berg; G Lindstedt; M Suurküla; S Jansson
Journal:  J Endocrinol Invest       Date:  2002-01       Impact factor: 4.256

Review 6.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

7.  The use of recombinant human TSH in a patient with metastatic follicular carcinoma and insufficient endogenous TSH production.

Authors:  M Luster; W Reinhardt; C Korber; M Lassmann; H Haenscheid; U Michalowski; J Rendl; E Eising; K Mann; C Reiners
Journal:  J Endocrinol Invest       Date:  2000 Jul-Aug       Impact factor: 4.256

8.  Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid carcinoma: a single-centre study of 54 patients.

Authors:  Barbara Jarzab; Daria Handkiewicz-Junak; Józef Roskosz; Zbigniew Puch; Zbigniew Wygoda; Aleksandra Kukulska; Beata Jurecka-Lubieniecka; Kornelia Hasse-Lazar; Maria Turska; Aleksander Zajusz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-29       Impact factor: 9.236

9.  Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy.

Authors:  Bart de Keizer; Boudewijn Brans; Anne Hoekstra; Pierre M J Zelissen; Hans P F Koppeschaar; Cees J M Lips; Peter P van Rijk; Rudi A Dierckx; John M H de Klerk
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-12-19       Impact factor: 9.236

10.  Adjuvant treatment with thyrotropin alpha for remnant ablation in thyroid cancer.

Authors:  Bernadette Biondi; Melania Pulcrano; Loredana Pagano; Gaetano Lombardi
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.